Literature DB >> 18354211

Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model.

John R Lukens1, Michael W Cruise, Matthew G Lassen, Young S Hahn.   

Abstract

The impaired function of CD8(+) T cells is characteristic of hepatitis C virus (HCV) persistent infection. HCV core protein has been reported to inhibit CD8(+) T cell responses. To determine the mechanism of the HCV core in suppressing Ag-specific CD8(+) T cell responses, we generated a transgenic mouse, core(+) mice, where the expression of core protein is directed to the liver using the albumin promoter. Using a recombinant adenovirus to deliver Ag, we demonstrated that core(+) mice failed to clear adenovirus-LacZ (Ad-LacZ) infection in the liver. The effector function of LacZ-specific CD8(+) T cells was particularly impaired in the livers of core(+) mice, with suppression of IFN-gamma, TNF-alpha, and granzyme B production by CD8(+) T cells. In addition, the impaired CD8(+) T cell responses in core(+) mice were accompanied by the enhanced expression of the inhibitory receptor programmed death-1 (PD-1) by LacZ-specific CD8(+) T cells and its ligand B7-H1 on liver dendritic cells following Ad-LacZ infection. Importantly, blockade of the PD-1/B7-H1 inhibitory pathway (using a B7-H1 blocking antibody) in core(+) mice enhanced effector function of CD8(+) T cells and cleared Ad-LacZ-infection as compared with that in mice treated with control Ab. This suggests that the regulation of the PD-1/B7-H1 inhibitory pathway is crucial for HCV core-mediated impaired T cell responses and viral persistence in the liver. This also suggests that manipulation of the PD-1/B7-H1 pathway may be a potential immunotherapy to enhance effector T cell responses during persistent HCV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18354211      PMCID: PMC2904552          DOI: 10.4049/jimmunol.180.7.4875

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  Programmed death-1-programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen.

Authors:  Osamu Aramaki; Nozomu Shirasugi; Tadatoshi Takayama; Motohide Shimazu; Masaki Kitajima; Yoshifumi Ikeda; Miyuki Azuma; Ko Okumura; Hideo Yagita; Masanori Niimi
Journal:  Transplantation       Date:  2004-01-15       Impact factor: 4.939

Review 2.  Hepatic T cells and liver tolerance.

Authors:  Ian Nicholas Crispe
Journal:  Nat Rev Immunol       Date:  2003-01       Impact factor: 53.106

3.  B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes.

Authors:  Haidong Dong; Gefeng Zhu; Koji Tamada; Dallas B Flies; Jan M A van Deursen; Lieping Chen
Journal:  Immunity       Date:  2004-03       Impact factor: 31.745

4.  CTL access to tissue antigen is restricted in vivo.

Authors:  K Ando; L G Guidotti; A Cerny; T Ishikawa; F V Chisari
Journal:  J Immunol       Date:  1994-07-15       Impact factor: 5.422

5.  The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection.

Authors:  Anthony J Freeman; Yong Pan; Charles E Harvey; Jeffrey J Post; Matthew G Law; Peter A White; William D Rawlinson; Andrew R Lloyd; George Marinos; Rosemary A Ffrench
Journal:  J Hepatol       Date:  2003-03       Impact factor: 25.083

6.  Hepatitis C virus core selectively suppresses interleukin-12 synthesis in human macrophages by interfering with AP-1 activation.

Authors:  Audrey L Eisen-Vandervelde; Stephen N Waggoner; Zhi Qiang Yao; Evan M Cale; Chang S Hahn; Young S Hahn
Journal:  J Biol Chem       Date:  2004-07-30       Impact factor: 5.157

7.  Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection.

Authors:  Daniele Accapezzato; Vittorio Francavilla; Marino Paroli; Marco Casciaro; Lucia Valeria Chircu; Agostino Cividini; Sergio Abrignani; Mario U Mondelli; Vincenzo Barnaba
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 8.  Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion?

Authors:  Young S Hahn
Journal:  Curr Opin Immunol       Date:  2003-08       Impact factor: 7.486

9.  PD-1 inhibits antiviral immunity at the effector phase in the liver.

Authors:  Yoshiko Iwai; Seigo Terawaki; Masaya Ikegawa; Taku Okazaki; Tasuku Honjo
Journal:  J Exp Med       Date:  2003-07-07       Impact factor: 14.307

10.  B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.

Authors:  Xingluo Liu; Jian Xin Gao; Jing Wen; Lijie Yin; Ou Li; Tao Zuo; Thomas F Gajewski; Yang-Xin Fu; Pan Zheng; Yang Liu
Journal:  J Exp Med       Date:  2003-06-16       Impact factor: 14.307

View more
  35 in total

1.  Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.

Authors:  Ping Yu; Jason C Steel; Meili Zhang; John C Morris; Thomas A Waldmann
Journal:  Clin Cancer Res       Date:  2010-10-05       Impact factor: 12.531

2.  Point mutation in the glycoprotein of lymphocytic choriomeningitis virus is necessary for receptor binding, dendritic cell infection, and long-term persistence.

Authors:  Brian M Sullivan; Sébastien F Emonet; Megan J Welch; Andrew M Lee; Kevin P Campbell; Juan C de la Torre; Michael B Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-26       Impact factor: 11.205

3.  PD-1-mediated attrition of polyfunctional memory CD8+ T cells in chronic toxoplasma infection.

Authors:  Rajarshi Bhadra; Jason P Gigley; Imtiaz A Khan
Journal:  J Infect Dis       Date:  2012-04-26       Impact factor: 5.226

4.  Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma.

Authors:  Liancai Wang; Qingyong Ma; Xiangli Chen; Kun Guo; Junhui Li; Min Zhang
Journal:  World J Surg       Date:  2010-05       Impact factor: 3.352

5.  Impaired hepatitis B vaccine responses during chronic hepatitis C infection: involvement of the PD-1 pathway in regulating CD4(+) T cell responses.

Authors:  Jonathan P Moorman; Chun L Zhang; Lei Ni; Cheng J Ma; Ying Zhang; Xiao Y Wu; Penny Thayer; Tareq M Islam; Thomas Borthwick; Zhi Q Yao
Journal:  Vaccine       Date:  2011-03-03       Impact factor: 3.641

Review 6.  Immune checkpoint inhibitors in challenging populations.

Authors:  Douglas B Johnson; Ryan J Sullivan; Alexander M Menzies
Journal:  Cancer       Date:  2017-02-27       Impact factor: 6.860

7.  Liver is able to activate naïve CD8+ T cells with dysfunctional anti-viral activity in the murine system.

Authors:  John R Lukens; Joseph S Dolina; Taeg S Kim; Robert S Tacke; Young S Hahn
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

8.  Deficiency in B7-H1 (PD-L1)/PD-1 coinhibition triggers pancreatic beta-cell destruction by insulin-specific, murine CD8 T-cells.

Authors:  Tarvo Rajasalu; Helen Brosi; Cornelia Schuster; Andreas Spyrantis; Bernhard Otto Boehm; Lieping Chen; Jörg Reimann; Reinhold Schirmbeck
Journal:  Diabetes       Date:  2010-05-18       Impact factor: 9.461

Review 9.  Recent Advances in Development of DNA Vaccines Against Hepatitis C virus.

Authors:  Sami Ullah; Muhammad Ali A Shah; Nosheen Riaz
Journal:  Indian J Virol       Date:  2012-03-20

10.  Old and rising stars in the lymphoid liver.

Authors:  Carlo Selmi; Mauro Podda; M Eric Gershwin
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.